Literature DB >> 11990379

Pharmacogenetics of the arylamine N-acetyltransferases.

N J Butcher1, S Boukouvala, E Sim, R F Minchin.   

Abstract

The arylamine N-acetyltransferases (NATs) are involved in the metabolism of a variety of different compounds that we are exposed to on a daily basis. Many drugs and chemicals found in the environment, such as those in cigarette smoke, car exhaust fumes and in foodstuffs, can be either detoxified by NATs and eliminated from the body or bioactivated to metabolites that have the potential to cause toxicity and/or cancer. NATs have been implicated in some adverse drug reactions and as risk factors for several different types of cancers. As a result, the levels of NATs in the body have important consequences with regard to an individual's susceptibility to certain drug-induced toxicities and cancers. This review focuses on recent advances in the molecular genetics of the human NATs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11990379     DOI: 10.1038/sj.tpj.6500053

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  46 in total

1.  Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase.

Authors:  Isaac M Westwood; Simon J Holton; Fernando Rodrigues-Lima; Jean-Marie Dupret; Sanjib Bhakta; Martin E M Noble; Edith Sim
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

2.  Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues.

Authors:  Sun Jung Kim; Han-Sung Kang; So-Youn Jung; Sun Young Min; Seeyoun Lee; Seok Won Kim; Youngmee Kwon; Keun Seok Lee; Kyung Hwan Shin; Jungsil Ro
Journal:  J Mol Med (Berl)       Date:  2010-07-14       Impact factor: 4.599

3.  Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population.

Authors:  A Touré; C Diop; M Cabral; M Fall; M Lhermitte; A Diouf; F Broly; D Allorge
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

Review 4.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

5.  Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities.

Authors:  Neville J Butcher; Ajanthy Arulpragasam; Hui Li Goh; Tamara Davey; Rodney F Minchin
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

6.  Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.

Authors:  Neera Singh; Sudhisha Dubey; Saravanan Chinnaraj; Anil Golani; Anurupa Maitra
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

7.  Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature.

Authors:  Rika Yuliwulandari; Qomariyah Sachrowardi; Nao Nishida; Miwa Takasu; Lilian Batubara; Tri Panjiasih Susmiarsih; Jecti Teguh Rochani; Riyani Wikaningrum; Risa Miyashita; Taku Miyagawa; Abdul Salam Mudzakir Sofro; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2007-12-27       Impact factor: 3.172

8.  Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-02-07       Impact factor: 3.922

9.  Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis.

Authors:  Youyang Zheng; Yong Li; Yaoshu Teng; Zhen Zhang; Xiaolin Cao
Journal:  Oncol Lett       Date:  2011-11-24       Impact factor: 2.967

10.  Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

Authors:  Alexander Jetter; Martina Kinzig; Michael Rodamer; Dorota Tomalik-Scharte; Fritz Sörgel; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.